

Special Issue

Approaches to Modulate the Effects of Drug Transporters for Drug Delivery and Development

Message from the Guest Editor

Drug transporters are important determinants of the pharmacokinetics and pharmacodynamics of drugs. Clinically relevant transporter-mediated drug–drug interactions are of increasing interest in drug development. A proper understanding of drug transporters' roles in drug disposition allows reliable evaluation/prediction of pharmacokinetics, of changes due to disease progression or genetic polymorphisms, and of drug–drug interactions. This knowledge will be helpful for developing novel combination therapies, prodrug treatments, and formulation strategies for drug delivery. This Special Issue welcomes original research and/or review articles of drug delivery and development related to the in vitro, in vivo and ex vivo pharmacokinetics, transporter-mediated drug–drug interactions, modulation effects of drug transporters, novel combination therapies, prodrug treatments, formulation strategies for effective drug delivery and in vitro to in vivo correlation and extrapolation (IVIVC/E). This Special Issue will promote mechanistic understanding of transporter interactions with drugs to improve drug delivery and development.

Guest Editor

Dr. Guru Raghavendra Valicherla

Department of Pharmaceutical Sciences, University of Pittsburgh
School of Pharmacy, Magee-Womens Research Institute, 204 Craft
Avenue, Pittsburgh, PA 15213, USA

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/154080

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).